| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | 0.0093 | 0.8 |
| mRNA | BRD-K27188169 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.8 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.8 |
| mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.8 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |